search
Back to results

The Canadian Diabetes Prevention Program (CDPP)

Primary Purpose

Diabetes type2

Status
Active
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
DPP Curriculum for Lifestyle Intervention
Sponsored by
LMC Diabetes & Endocrinology Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Diabetes type2 focused on measuring Diabetes, Pre-diabetes, Diabetes prevention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Score of 33 or higher using the Canadian Diabetes Risk Assessment (CANRISK) Questionnaire (aged 18 to 74) or; Age ≥ 45 and BMI ≥ 30 or; Or diagnosed with prediabetes age 18 years or older with an A1c of 6.0-6.4% and/or fasting glucose 6.1-6.9 mmol/L and; Access to phone and internet (options include: home, work, friend's home, relative's home, public library, etc.); Exclusion Criteria: Diagnosis of diabetes Any glucose lowering medication Any prescribed weight loss medication Receiving oral/systemic glucocorticoid (steroid) therapy (not including inhalers or nasal sprays) within the past 3 months, or planning to initiate oral/systemic glucocorticoid (steroid) in the next 3 months History of acute or chronic pancreatitis History of an active or untreated malignancy or in remission from a clinically significant malignancy for less than 5 years History of hemoglobinopathy, which may affect HbA1c measurement Currently enrolled in a clinical trial involving an investigational drug (need to be free of study medication for 30 days after final visit) Pregnancy or becoming pregnant during the study (the participant would be excluded due to weight gain and increased of waist circumference as they contradict the outcomes of the study) Dementia/severe cognitive impairment (the study does not have the proper support staff to support participants with specific needs) Inability to read English or French, or with personal or family support to interpret material Outside the catchment area for lab services (blood and anthropometric collection) Weight at baseline greater than upper limit of the scale used

Sites / Locations

  • LMC Diabetes Ltd

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

DPP

Arm Description

The CDC Diabetes Prevention Program (DPP) curriculum for lifestyle intervention, including 21 education topics delivered via text-based education module, and follow-up telephone health coaching call for each topic.

Outcomes

Primary Outcome Measures

Change in weight assessed by a scale
Change in weight assessed by a scale
BMI < 25.0 and/or weight loss ≥ 5.0%
BMI < 25.0 and/or weight loss ≥ 5.0%
Change in waist circumference assessed by measurement in waist circumference
> 3% and ≥ 5% reduction in waist circumference
> 3% and ≥ 5% reduction in waist circumference
A1c at final visit <6.5% measured by lab test
A1c at final visit <6.5% measured by lab test
Fasting blood glucose at final visit < 7 mmol/L measured by lab test
Fasting blood glucose at final visit < 7 mmol/L measured by lab test

Secondary Outcome Measures

Number of participants in each category and sub-category (of each question) of CANRISK Questionnaire
Number of participants that are diagnosed with prediabetes vs. at high risk
The number of people who develop diabetes during the program
Effectiveness of recruitment channels.
The following choices will be given to participants to fill out and the participant will be able to choose all that apply: doctor or health care provider, social media (facebook, instagram, twitter) google/internet search, employer, recommendation from family/friend, and/or other.
Intervention reach assessed by postal code
Participants knowledge about disease risk factors and lifestyle change assessed through the Knowledge Questionnaire
The proportion of individuals who lower their risk of diabetes (CANRISK score)
The proportion of participants who had an improvement in quality of life assessed by the SF-12 Questionnaire
The proportion of participants who had a change in diet, based on ASA-24 Questionnaire
The number of participants in each category of the stages of change assessed by the Stages of Change Questionnaire
Participants change in the stage of change assessed by Stages of Change Questionnaire
The number of participants who completed the program
A completed participant is defined as someone who attended 56% of their sessions in the first 6 months of intervention, and at least 50% of their sessions in the last 6 months of their intervention, and has been in the program for a minimum of 9 months in total
Participant satisfaction by Participant Satisfaction Survey and Post Program Interview
The proportion of participants who had a change in physical activity
The proportion of participants who report a minimum of 150 minutes of moderate- to vigorous-intensity of physical activity spread across the week.
The INTERVENT platform has the ability to measure participants' steps if they have a step-counter; therefore, the amount of time will be identified as self-reported or through a step counter.
Change in LDL-c and non-HDL (subgroup analyses for people on cholesterol lowering medications vs. no cholesterol lowering medications during the project)
Change in HDL
Change in triglycerides
Proportion of subjects with improvement of triglyceride levels within normal limit for the lab
Change in blood pressure
Both systolic and diastolic blood pressure will be measured.

Full Information

First Posted
October 22, 2021
Last Updated
March 14, 2023
Sponsor
LMC Diabetes & Endocrinology Ltd.
Collaborators
Public Health Agency of Canada (PHAC)
search

1. Study Identification

Unique Protocol Identification Number
NCT05784220
Brief Title
The Canadian Diabetes Prevention Program
Acronym
CDPP
Official Title
Prevention of Type 2 Diabetes Using a Digital Wellness Coaching Intervention: The Canadian Diabetes Prevention Program
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 21, 2019 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
September 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
LMC Diabetes & Endocrinology Ltd.
Collaborators
Public Health Agency of Canada (PHAC)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
According to Diabetes Canada ("DC"), in 2015, the estimated prevalence of prediabetes in Canada (>20 years of age) is 5.7 million people (22.1%). This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently Type 2 Diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada . There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes.
Detailed Description
INTRODUCTION: LMC Healthcare, in collaboration with Diabetes Canada and INTERVENT International, is inviting participants to be part of a new program called the Canadian Diabetes Prevention Program ("CDPP") aimed at reducing the risk of developing Type 2 Diabetes. Participants can join the CDPP if participants have been diagnosed with prediabetes or participants score 33 or above on the CANRISK Questionnaire (a validated tool used to assess diabetes risk). Information collected from the CDPP will be used for research purposes. BACKGROUND / RATIONALE: According to Diabetes Canada ("DC"), in 2015, the estimated number of people with prediabetes in Canada (>20 years of age) was 5.7 million people (22.1%). Prediabetes can be defined as people with a blood sugar level that is higher than normal but not high enough to be diagnosed with diabetes; these people are at high risk for developing diabetes. This rate is estimated to increase to 6.4 million people (23.2%) by 2025. Risk factors contributing to prediabetes and consequently type 2 diabetes include rising obesity rates, lack of physical activity, an aging population, and the cultural diversity of Canada. There is convincing evidence that modifiable risk factors, such as diet and physical activity reduce the development of Type 2 Diabetes with the benefits extending beyond the active intervention stage. The underlying theory that supports this intervention relates to the imperative need to focus on weight loss and physical activity, with this population that is at risk of developing diabetes, due to its relationship with insulin resistance. DC outlines the importance of intensive and structured lifestyle modification to promote weight loss in order to reduce the progression of prediabetes to diabetes. The proposed intervention would target participants who are identified as "at risk" using the Canadian Diabetes Risk Assessment Questionnaire (CANRISK) or those participants who have been diagnosed with prediabetes based on blood work. PURPOSE/OBJECTIVE: To reduce the risk of developing Type 2 Diabetes Mellitus by taking part in a 12-month lifestyle intervention program. A select group of participants, 452 participants, will have a follow up at 18 months to assess a post-study progression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes type2
Keywords
Diabetes, Pre-diabetes, Diabetes prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
No masking
Allocation
N/A
Enrollment
2174 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DPP
Arm Type
Other
Arm Description
The CDC Diabetes Prevention Program (DPP) curriculum for lifestyle intervention, including 21 education topics delivered via text-based education module, and follow-up telephone health coaching call for each topic.
Intervention Type
Behavioral
Intervention Name(s)
DPP Curriculum for Lifestyle Intervention
Intervention Description
See arms.
Primary Outcome Measure Information:
Title
Change in weight assessed by a scale
Time Frame
12 months from baseline
Title
Change in weight assessed by a scale
Time Frame
18 months from baseline
Title
BMI < 25.0 and/or weight loss ≥ 5.0%
Time Frame
12 months from baseline
Title
BMI < 25.0 and/or weight loss ≥ 5.0%
Time Frame
18 months from baseline
Title
Change in waist circumference assessed by measurement in waist circumference
Time Frame
12 months from baseline
Title
> 3% and ≥ 5% reduction in waist circumference
Time Frame
12 months from baseline
Title
> 3% and ≥ 5% reduction in waist circumference
Time Frame
18 months from baseline
Title
A1c at final visit <6.5% measured by lab test
Time Frame
12 months from baseline
Title
A1c at final visit <6.5% measured by lab test
Time Frame
18 months from baseline
Title
Fasting blood glucose at final visit < 7 mmol/L measured by lab test
Time Frame
12 months from baseline
Title
Fasting blood glucose at final visit < 7 mmol/L measured by lab test
Time Frame
8 months from baseline
Secondary Outcome Measure Information:
Title
Number of participants in each category and sub-category (of each question) of CANRISK Questionnaire
Time Frame
Baseline, 6 months and 12 months
Title
Number of participants that are diagnosed with prediabetes vs. at high risk
Time Frame
Baseline, 6 months and 12 months
Title
The number of people who develop diabetes during the program
Time Frame
6 months and 12 months
Title
Effectiveness of recruitment channels.
Description
The following choices will be given to participants to fill out and the participant will be able to choose all that apply: doctor or health care provider, social media (facebook, instagram, twitter) google/internet search, employer, recommendation from family/friend, and/or other.
Time Frame
Baseline
Title
Intervention reach assessed by postal code
Time Frame
Baseline
Title
Participants knowledge about disease risk factors and lifestyle change assessed through the Knowledge Questionnaire
Time Frame
Baseline, 6 months and 12 months
Title
The proportion of individuals who lower their risk of diabetes (CANRISK score)
Time Frame
6 months and 12 months
Title
The proportion of participants who had an improvement in quality of life assessed by the SF-12 Questionnaire
Time Frame
6 months and 12 months
Title
The proportion of participants who had a change in diet, based on ASA-24 Questionnaire
Time Frame
6 months and 12 months
Title
The number of participants in each category of the stages of change assessed by the Stages of Change Questionnaire
Time Frame
Baseline, 6 months and 12 months
Title
Participants change in the stage of change assessed by Stages of Change Questionnaire
Time Frame
6 months and 12 months
Title
The number of participants who completed the program
Description
A completed participant is defined as someone who attended 56% of their sessions in the first 6 months of intervention, and at least 50% of their sessions in the last 6 months of their intervention, and has been in the program for a minimum of 9 months in total
Time Frame
9 months
Title
Participant satisfaction by Participant Satisfaction Survey and Post Program Interview
Time Frame
6 months and 12 months
Title
The proportion of participants who had a change in physical activity
Time Frame
6 months and 12 months
Title
The proportion of participants who report a minimum of 150 minutes of moderate- to vigorous-intensity of physical activity spread across the week.
Description
The INTERVENT platform has the ability to measure participants' steps if they have a step-counter; therefore, the amount of time will be identified as self-reported or through a step counter.
Time Frame
Baseline, 6 months and 12 months
Title
Change in LDL-c and non-HDL (subgroup analyses for people on cholesterol lowering medications vs. no cholesterol lowering medications during the project)
Time Frame
12 months
Title
Change in HDL
Time Frame
12 months
Title
Change in triglycerides
Time Frame
12 months
Title
Proportion of subjects with improvement of triglyceride levels within normal limit for the lab
Time Frame
12 months
Title
Change in blood pressure
Description
Both systolic and diastolic blood pressure will be measured.
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
The number of reported technical issues related to software
Time Frame
12 months
Title
Level of participant engagement
Time Frame
6 months and 12 months
Title
Issues with delivery by service providers
Time Frame
12 months from baseline
Title
Subjective scoring of program coach audits
Description
0-10, A higher number is a better result
Time Frame
12 months from baseline
Title
Objective scoring of program coach audits
Description
0-5. A higher number is a better result
Time Frame
12 months from baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Score of 33 or higher using the Canadian Diabetes Risk Assessment (CANRISK) Questionnaire (aged 18 to 74) or; Age ≥ 45 and BMI ≥ 30 or; Or diagnosed with prediabetes age 18 years or older with an A1c of 6.0-6.4% and/or fasting glucose 6.1-6.9 mmol/L and; Access to phone and internet (options include: home, work, friend's home, relative's home, public library, etc.); Exclusion Criteria: Diagnosis of diabetes Any glucose lowering medication Any prescribed weight loss medication Receiving oral/systemic glucocorticoid (steroid) therapy (not including inhalers or nasal sprays) within the past 3 months, or planning to initiate oral/systemic glucocorticoid (steroid) in the next 3 months History of acute or chronic pancreatitis History of an active or untreated malignancy or in remission from a clinically significant malignancy for less than 5 years History of hemoglobinopathy, which may affect HbA1c measurement Currently enrolled in a clinical trial involving an investigational drug (need to be free of study medication for 30 days after final visit) Pregnancy or becoming pregnant during the study (the participant would be excluded due to weight gain and increased of waist circumference as they contradict the outcomes of the study) Dementia/severe cognitive impairment (the study does not have the proper support staff to support participants with specific needs) Inability to read English or French, or with personal or family support to interpret material Outside the catchment area for lab services (blood and anthropometric collection) Weight at baseline greater than upper limit of the scale used
Facility Information:
Facility Name
LMC Diabetes Ltd
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4G 3E8
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The Canadian Diabetes Prevention Program

We'll reach out to this number within 24 hrs